Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Cutting both ways: the innate immune response to oncolytic virotherapy
by
McCart, J. Andrea
, Mealiea, David
in
Antitumor activity
/ Antiviral activity
/ Antiviral drugs
/ Cell activation
/ Dendritic cells
/ Immune response
/ Immunosuppression
/ Immunotherapy
/ Innate immunity
/ Leukocytes (neutrophilic)
/ Macrophages
/ Natural killer cells
/ Oncolysis
/ Suppressor cells
/ Therapeutic targets
/ Tumor microenvironment
/ Tumors
2022
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cutting both ways: the innate immune response to oncolytic virotherapy
by
McCart, J. Andrea
, Mealiea, David
in
Antitumor activity
/ Antiviral activity
/ Antiviral drugs
/ Cell activation
/ Dendritic cells
/ Immune response
/ Immunosuppression
/ Immunotherapy
/ Innate immunity
/ Leukocytes (neutrophilic)
/ Macrophages
/ Natural killer cells
/ Oncolysis
/ Suppressor cells
/ Therapeutic targets
/ Tumor microenvironment
/ Tumors
2022
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Cutting both ways: the innate immune response to oncolytic virotherapy
by
McCart, J. Andrea
, Mealiea, David
in
Antitumor activity
/ Antiviral activity
/ Antiviral drugs
/ Cell activation
/ Dendritic cells
/ Immune response
/ Immunosuppression
/ Immunotherapy
/ Innate immunity
/ Leukocytes (neutrophilic)
/ Macrophages
/ Natural killer cells
/ Oncolysis
/ Suppressor cells
/ Therapeutic targets
/ Tumor microenvironment
/ Tumors
2022
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Cutting both ways: the innate immune response to oncolytic virotherapy
Journal Article
Cutting both ways: the innate immune response to oncolytic virotherapy
2022
Request Book From Autostore
and Choose the Collection Method
Overview
Oncolytic viruses (OVs), above and beyond infecting and lysing malignant cells, interact with the immune system in complex ways that have important therapeutic significance. While investigation into these interactions is still in its early stages, important insights have been made over the past two decades that will help improve the clinical efficacy of OV-based management strategies in cancer care moving forward. The inherent immunosuppression that defines the tumor microenvironment can be modified by OV infection, and the subsequent recruitment and activation of innate immune cells, in particular, is central to this. Indeed, neutrophils, macrophages, natural killer cells, and dendritic cells, as well as other populations such as myeloid-derived suppressor cells, are key to the immune escape that allows tumors to survive, but their natural response to infection can be exploited by virotherapy. While stimulation of innate immune cells by OVs can initiate antitumor responses, related antiviral activity can limit virus spread and direct cytopathogenic effects. In this review, we highlight how each innate immune cell population influences this balance of antitumor and antiviral forces during virotherapy, some of the important molecular pathways that have been identified, and specific therapeutic targets that have emerged through this work. We discuss the importance of OV-based combination therapies in optimizing antiviral and antitumor innate immune responses stimulated by virotherapy toward tumor eradication, and how these processes vary depending on the tumor and OV in question. Rather than concentrating on a particular OV species in the review, we present the range of effects that have been documented across OV types to emphasize the context-specific nature of these interactions and how this is important in the design of future OV-based treatment approaches.
Publisher
Nature Publishing Group
Subject
/ Tumors
This website uses cookies to ensure you get the best experience on our website.